New study examines pain and adherence in patients switching to concentrated adalimumab
NCT ID NCT05913817
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration form of adalimumab (AVT-02). Researchers measured injection site pain and how well patients stuck with their treatment over 180 days. The goal was to see if the new formulation causes less pain and improves quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
JAMP Pharma Corporation
Montreal, Quebec, J4B 5H3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a patient registry unlock the secrets of IBD?
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out